Completed OBSERVATIONAL NCT02247310

BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon

BETAEVAL_Global- The New BETACONNECT® Auto-injector: Adherence and EVALuation of MS Patients Treated With Betaferon®

Sponsor: Bayer

Conditions Multiple Sclerosis, Relapsing Remitting

Interventions BETACONNECT Interferon beta-1b (Betaferon®, BAY 86-5046)

Updated 8 times since 2017 Last updated: Nov 5, 2017 Started: Oct 20, 2014 Primary completion: Jul 19, 2016 Completion: Nov 8, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Multiple Sclerosis, Relapsing Remitting, this trial is completed. The trial is conducted by Bayer and has accumulated 8 data snapshots since 2014. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed
Sep 2024 — Sep 2025 [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed
Jun 2018 — Jan 2021 [monthly]

Completed

▶ Show 3 earlier versions

Apr 2018 — Jun 2018 [monthly]

Completed

Phase: NA → None
Dec 2017 — Apr 2018 [monthly]

Completed NA
Jan 2017 — Dec 2017 [monthly]

Completed NA

First recorded

Oct 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bayer

Data source: Bayer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Many Locations, Austria , Many Locations, Belgium , Many Locations, Bosnia and Herzegovina , Many Locations, Croatia , Many Locations, Czechia , Many Locations, France , Many Locations, Greece , Many Locations, Hungary , Many Locations, Italy , Many Locations, Spain and 1 more location